Dormosedan (Detomidine HCl)
Detomidine hydrochloride, a synthetic alpha-2 adrenoreceptor agonist with sedative and analgesic properties. For use in horses only.
DORMOSEDAN�
Zoetis
(detomidine hydrochloride)
Sedative and Analgesic For Use in Horses Only
Sterile Solution
10 mg/mL
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
DESCRIPTION: Dormosedan� is a synthetic alpha-2 adrenoreceptor agonist with sedative and analgesic properties. The chemical name is 1H imidazole, 4-[(2,3-dimethylphenyl) methyl]-hydrochloride and the generic name is detomidine hydrochloride. It is a white, crystalline, water-soluble substance having a molecular weight of 222.7. The molecular formula is C12H14N2�HCl.
WARNINGS: Do not use in horses intended for human consumption. Not for human use. Keep out of reach of children.
ADVERSE REACTIONS: Occasional reports of anaphylactic-like reactions have been received, including 1 or more of the following: urticaria, skin plaques, dyspnea, edema of the upper airways, trembling, recumbency, and death. The use of epinephrine should be avoided since epinephrine may potentiate the effects of α2-agonists. Reports of mild adverse reactions have resolved uneventfully without treatment. Severe adverse reactions should be treated symptomatically. As with all α2-agonists, the potential for isolated cases of hypersensitivity exist, including paradoxical response (excitation).
SIDE EFFECTS: Horses treated with Dormosedan� exhibit hypertension. Bradycardia routinely occurs 1 minute after injection. The relationship between hypertension and bradycardia is consistent with an adaptive baroreceptor response to the increased pressure and inconsistent with a primary drug-induced bradycardia. Piloerection, sweating, salivation, and slight muscle tremors are frequently seen after administration. Partial transient penis prolapse may be seen. Partial AV and SA blocks may occur with decreased heart and respiratory rates. Urination typically occurs during recovery at about 45-60 minutes posttreatment, depending on dosage. Incoordination or staggering is usually seen only during the first 3-5 minutes after injection, until animals have secured a firm footing.
DOSAGE AND ADMINISTRATION:
For Sedation: Administer Dormosedan� IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan� per 100 kg or 220 lb), depending on the depth and duration of sedation required. Onset of sedative effects should be reached within 2-4 minutes after IV administration and 3-5 minutes after IM administration. Twenty mcg/kg will provide 30-90 minutes of sedation and 40 mcg/kg will provide approximately 90 minutes to 2 hours of sedation.
For Analgesia: Administer Dormosedan� IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan� per 100 kg or 220 lb), depending on the depth and duration of analgesia required. Twenty mcg/kg will usually begin to take effect in 2-4 minutes and provide 30-45 minutes of analgesia. The 40 mcg/kg dose will also begin to take effect in 2-4 minutes and provide 45-75 minutes of analgesia.
For Both Sedation and Analgesia: Administer Dormosedan� IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan� per 100 kg or 220 lb), depending on the depth and duration of sedation and analgesia required.
Before and after injection, the animal should be allowed to rest quietly.
STORAGE: Store at controlled room temperature 15�-30�C (59�-86�F) in the absence of light.
HOW SUPPLIED: Dormosedan� is supplied in 5- and 20-mL multidose vials.
